Renalytix Plc (LON:RENX – Get Free Report)’s share price rose 18.5% during mid-day trading on Friday . The company traded as high as GBX 3.90 and last traded at GBX 3.85. Approximately 2,615,687 shares were traded during trading, an increase of 197% from the average session volume of 881,370 shares. The stock had previously closed at GBX 3.25.
Renalytix Stock Up 18.5%
The firm’s 50 day simple moving average is GBX 2.36 and its 200 day simple moving average is GBX 2.84. The company has a market cap of £16.83 million, a price-to-earnings ratio of -0.96 and a beta of 1.81. The company has a quick ratio of 2.42, a current ratio of 1.57 and a debt-to-equity ratio of -483.33.
Renalytix Company Profile
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
See Also
- Five stocks we like better than Renalytix
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
